A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer

NCT07143292 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Cervical Cancer Metastatic
Cervical Cancer Recurrent

Interventions

DRUG: Famitinib + Camrelizumab

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University